NCT06980350 2025-07-29
Proposal of a Novel Model for Identifying Complete Response in dMMR Colon Cancer Following Neoadjuvant Immunotherapy
Sun Yat-sen University
Completed
Clinical Trials
7 trialsNCT06835179 2025-02-19
SBRT Combined With CAPEOX, Bevacizumab, and PD-1 Inhibitor for the Treatment of RAS-Mutant, MSS-Type, Unresectable Metastatic Colorectal Cancer.
The First Affiliated Hospital with Nanjing Medical University
Phase 2 Not yet recruiting
NCT06543836 2024-08-09
ctDNA-guided Treatment of TKI Plus PD-1 Inhibitor for Advanced pMMR/MSS Colorectal Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2 Recruiting
NCT04715633 2024-07-09
PD-1 Inhibitors Combined With VEGF Inhibitors for Locally Advanced dMMR/MSI-H Colorectal Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT06031376 2023-09-11
Fruquintinib With PD-1 Inhibitors Versus TAS-102 With Bevacizumab in Late-Line mCRC
Hunan Cancer Hospital
Completed
NCT06011330 2023-08-30
Fruquintinib Plus PD-1 in Refractory MSS Metastatic Colorectal Cancer
Hunan Cancer Hospital
Completed
NCT05371197 2022-05-12
Envafolimab as Neoadjuvant Immuntherapy in Resectable Local Advanced dMMR/MSI-H Colorectal Cancer
Third Affiliated Hospital, Sun Yat-Sen University
Phase 2 Unknown